Sign In
Buy SNY
$44.38
+2.01 (+4.74%)
At Close: Jun 04, 2026
Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting
07:19am, Sunday, 16'th Jun 2024
Sanofi's shares have not fully recovered since announcing a business strategy change in October 2023, focusing on R&D investments and on separating its consumer healthcare business unit. The company's
Sanofi: A Leader In Life-Saving Vaccines And Treatments
05:06am, Friday, 14'th Jun 2024
In recent weeks, Sanofi has pleased investors with progress in the development of its pipeline of experimental drugs. On May 20, 2024, SNY announced additional results from a Phase 3 clinical trial th
A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge
07:30am, Wednesday, 12'th Jun 2024
Artificial intelligence is forecast to drive an innovation bonanza in healthcare. This innovation boom is expected to increase the human lifespan dramatically.
Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi
02:42pm, Friday, 07'th Jun 2024
Inhibrx Biosciences, Inc.'s INBRX-109 is a tetravalent drug being developed for the treatment of patients with Ewing Sarcoma and other solid tumor types. It is expected that the Ewing Sarcoma Therapeu
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces the launch of its Virtual Control Groups (VCG) initiative with Sanofi to reduce the use of animals in research.
ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
3 Dividend Stocks to Buy in June 2024 for Dependable Dividend Growth
02:38pm, Monday, 03'rd Jun 2024
Investing in dividend growth stocks is a popular strategy for those seeking a dependable income stream and potential capital appreciation. As we step into June 2024, identifying the right stocks with
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
10:36am, Friday, 31'st May 2024
Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.
Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
06:00am, Friday, 31'st May 2024
Sanofi launches 2024 global Employee Stock Purchase Plan Paris, May 31, 2024. Sanofi's global employee shareholder plan, Action 2024, opens on June 4, 2024, to around 80,000 employees in 56 countries.
FDA extends deadline, requests more data on Sanofi's Dupixent for treating 'smoker's lung'
01:31am, Friday, 31'st May 2024
French drugmaker Sanofi and its partner Regeneron said on Friday the U.S. Food and Drug Administration (FDA) requested additional analyses on the efficacy of Dupixent as an add-on treatment in certain
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
01:05am, Friday, 31'st May 2024
Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 tria
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
01:00am, Friday, 31'st May 2024
Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation Paris and Tarrytown, NY May 31, 2024. The US Food and Drug Administration (FDA) has extended by th
Press Release: Sanofi completes acquisition of Inhibrx, Inc.
09:01am, Thursday, 30'th May 2024
Sanofi completes acquisition of Inhibrx, Inc. Paris, May 30, 2024. Sanofi announced today the completion of its acquisition of Inhibrx, Inc. (“Inhibrx”).
Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag
11:46am, Monday, 27'th May 2024
The FDA grants priority review to Sanofi's (SNY) sBLA for the Sarclisa combination regimen for transplant-ineligible newly diagnosed multiple myeloma. A decision is due on Sep 27, 2024.
Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase 3 study If
